Share Price and Basic Stock Data
Last Updated: December 11, 2025, 2:40 am
| PEG Ratio | 2.41 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Anuh Pharma Ltd operates in the pharmaceuticals sector and has shown a consistent growth trajectory in its revenue streams. For the fiscal year ending March 2025, the company reported sales of ₹662 Cr, up from ₹527 Cr in the previous year. This upward trend is encouraging for investors, as it indicates a robust demand for its products. The quarterly sales figures also paint a positive picture, with the latest recorded sales for June 2025 at ₹186.48 Cr, reflecting a solid performance despite some fluctuations in previous quarters. Notably, the company’s sales peaked at ₹198.14 Cr in March 2025, demonstrating its ability to generate significant revenue in a competitive marketplace. Over the years, Anuh Pharma has effectively navigated various market challenges, showcasing resilience and adaptability.
Profitability and Efficiency Metrics
On the profitability front, Anuh Pharma reported a net profit of ₹47 Cr for FY 2025, a slight decline from ₹60 Cr in FY 2024. This decline could raise eyebrows, especially when considering the company’s operating profit margin (OPM) which stood at a mere 9% for the same period. While the OPM is not alarming in the pharmaceutical sector, it does suggest that the company may be facing cost pressures. The interest coverage ratio (ICR) of 113.62x indicates that Anuh Pharma is comfortably positioned to meet its interest obligations, reflecting financial stability. However, the return on equity (ROE) at 14.52% could be seen as moderate, suggesting room for improvement in generating returns for shareholders. Overall, while profitability metrics show some strengths, the company might need to address its cost management strategies to optimize margins.
Balance Sheet Strength and Financial Ratios
Anuh Pharma’s balance sheet reveals a strong financial position, characterized by zero borrowings, which is a significant advantage in today’s volatile economic environment. The total reserves stood at ₹301 Cr as of March 2025, providing a solid cushion for future growth initiatives or unexpected challenges. The company’s current ratio of 2.11 indicates a healthy liquidity position, suggesting that it can cover its short-term liabilities comfortably. However, the price-to-book value (P/BV) ratio of 2.29x may suggest that the stock is trading at a premium compared to its book value. Investors might consider this a signal to watch for potential overvaluation. Overall, the financial ratios suggest that while Anuh Pharma is in a strong position, its valuation metrics warrant cautious scrutiny.
Shareholding Pattern and Investor Confidence
Anuh Pharma’s shareholding pattern shows a dominant promoter holding of 71.81%, which is reassuring for investors as it indicates a strong commitment from the company’s founders. However, the absence of Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) could be a red flag, as their participation often signals confidence in a company’s growth prospects. The public shareholding stands at 28.19%, which is relatively healthy, with a growing number of shareholders now totaling 28,250. This increase in shareholder base could be interpreted as a positive sign of retail investor interest, but the lack of institutional backing might raise concerns about the stock’s stability and wider market perception. Investor confidence, therefore, appears mixed and could hinge on future performance and strategic initiatives.
Outlook, Risks, and Final Insight
Looking ahead, Anuh Pharma appears to face a mix of opportunities and challenges. The company’s ability to sustain revenue growth is critical, especially as market dynamics evolve. One significant risk is the potential for rising operational costs, which could further pressure profit margins if not managed effectively. Additionally, the lack of institutional investment may limit the stock’s liquidity and could impact its market performance during downturns. On the other hand, the absence of debt positions the company well to take advantage of growth opportunities without the burden of interest payments. Investors should keep an eye on how Anuh Pharma navigates these challenges while capitalizing on its strengths. In a sector known for volatility, maintaining a keen perspective on both financial health and market trends will be vital for making informed investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Anuh Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 239/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,177 Cr. | 383 | 479/192 | 86.5 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,309.02 Cr | 1,154.03 | 52.38 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 116.38 | 115.07 | 138.73 | 157.31 | 161.48 | 149.53 | 172.10 | 163.89 | 137.91 | 165.95 | 159.51 | 198.14 | 186.48 |
| Expenses | 105.20 | 101.64 | 126.30 | 143.08 | 147.51 | 131.57 | 148.11 | 144.67 | 127.34 | 149.07 | 144.72 | 179.47 | 176.19 |
| Operating Profit | 11.18 | 13.43 | 12.43 | 14.23 | 13.97 | 17.96 | 23.99 | 19.22 | 10.57 | 16.88 | 14.79 | 18.67 | 10.29 |
| OPM % | 9.61% | 11.67% | 8.96% | 9.05% | 8.65% | 12.01% | 13.94% | 11.73% | 7.66% | 10.17% | 9.27% | 9.42% | 5.52% |
| Other Income | 0.96 | 2.01 | 2.11 | 1.04 | 3.47 | 2.15 | 3.66 | 2.82 | 3.72 | 3.40 | 0.94 | 1.40 | 3.39 |
| Interest | 0.06 | 0.11 | 0.03 | 0.02 | 0.02 | 0.09 | 0.14 | 0.10 | 0.14 | 0.16 | 0.28 | 0.03 | 0.21 |
| Depreciation | 2.42 | 2.44 | 2.43 | 2.41 | 2.01 | 2.15 | 2.20 | 2.23 | 1.88 | 1.92 | 2.18 | 2.76 | 2.52 |
| Profit before tax | 9.66 | 12.89 | 12.08 | 12.84 | 15.41 | 17.87 | 25.31 | 19.71 | 12.27 | 18.20 | 13.27 | 17.28 | 10.95 |
| Tax % | 24.12% | 23.04% | 22.93% | 25.08% | 23.75% | 22.61% | 24.46% | 22.12% | 22.49% | 17.31% | 22.00% | 27.95% | 24.20% |
| Net Profit | 7.34 | 9.92 | 9.31 | 9.62 | 11.75 | 13.83 | 19.11 | 15.36 | 9.51 | 15.04 | 10.34 | 12.46 | 8.30 |
| EPS in Rs | 0.73 | 0.99 | 0.93 | 0.96 | 1.17 | 1.38 | 1.91 | 1.53 | 0.95 | 1.50 | 1.03 | 1.24 | 0.83 |
Last Updated: August 19, 2025, 11:40 pm
Below is a detailed analysis of the quarterly data for Anuh Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 186.48 Cr.. The value appears to be declining and may need further review. It has decreased from 198.14 Cr. (Mar 2025) to 186.48 Cr., marking a decrease of 11.66 Cr..
- For Expenses, as of Jun 2025, the value is 176.19 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 179.47 Cr. (Mar 2025) to 176.19 Cr., marking a decrease of 3.28 Cr..
- For Operating Profit, as of Jun 2025, the value is 10.29 Cr.. The value appears to be declining and may need further review. It has decreased from 18.67 Cr. (Mar 2025) to 10.29 Cr., marking a decrease of 8.38 Cr..
- For OPM %, as of Jun 2025, the value is 5.52%. The value appears to be declining and may need further review. It has decreased from 9.42% (Mar 2025) to 5.52%, marking a decrease of 3.90%.
- For Other Income, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.40 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 1.99 Cr..
- For Interest, as of Jun 2025, the value is 0.21 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.03 Cr. (Mar 2025) to 0.21 Cr., marking an increase of 0.18 Cr..
- For Depreciation, as of Jun 2025, the value is 2.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.76 Cr. (Mar 2025) to 2.52 Cr., marking a decrease of 0.24 Cr..
- For Profit before tax, as of Jun 2025, the value is 10.95 Cr.. The value appears to be declining and may need further review. It has decreased from 17.28 Cr. (Mar 2025) to 10.95 Cr., marking a decrease of 6.33 Cr..
- For Tax %, as of Jun 2025, the value is 24.20%. The value appears to be improving (decreasing) as expected. It has decreased from 27.95% (Mar 2025) to 24.20%, marking a decrease of 3.75%.
- For Net Profit, as of Jun 2025, the value is 8.30 Cr.. The value appears to be declining and may need further review. It has decreased from 12.46 Cr. (Mar 2025) to 8.30 Cr., marking a decrease of 4.16 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.83. The value appears to be declining and may need further review. It has decreased from 1.24 (Mar 2025) to 0.83, marking a decrease of 0.41.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 7:34 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 266 | 284 | 326 | 206 | 238 | 321 | 307 | 432 | 487 | 527 | 647 | 662 | 710 |
| Expenses | 242 | 253 | 289 | 183 | 220 | 291 | 284 | 387 | 439 | 476 | 571 | 600 | 649 |
| Operating Profit | 24 | 31 | 38 | 23 | 18 | 30 | 23 | 45 | 47 | 52 | 76 | 62 | 61 |
| OPM % | 9% | 11% | 12% | 11% | 8% | 9% | 8% | 10% | 10% | 10% | 12% | 9% | 9% |
| Other Income | 4 | 5 | 4 | 8 | 7 | 5 | 4 | 11 | 5 | 6 | 12 | 9 | 9 |
| Interest | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 3 | 2 | 2 | 2 | 2 | 7 | 15 | 12 | 10 | 9 | 9 | 9 |
| Profit before tax | 25 | 32 | 38 | 28 | 23 | 32 | 19 | 39 | 39 | 47 | 78 | 61 | 60 |
| Tax % | 31% | 31% | 32% | 27% | 29% | 28% | 25% | 26% | 22% | 24% | 23% | 22% | |
| Net Profit | 18 | 22 | 26 | 20 | 17 | 23 | 14 | 28 | 31 | 36 | 60 | 47 | 46 |
| EPS in Rs | 1.76 | 2.19 | 2.57 | 2.00 | 1.65 | 2.33 | 1.43 | 2.84 | 3.05 | 3.61 | 5.99 | 4.73 | 4.60 |
| Dividend Payout % | 37% | 27% | 24% | 31% | 42% | 29% | 48% | 26% | 29% | 28% | 21% | 16% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.22% | 18.18% | -23.08% | -15.00% | 35.29% | -39.13% | 100.00% | 10.71% | 16.13% | 66.67% | -21.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -4.04% | -41.26% | 8.08% | 50.29% | -74.42% | 139.13% | -89.29% | 5.41% | 50.54% | -88.33% |
Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 17% |
| 3 Years: | 11% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 26% |
| 3 Years: | 13% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -3% |
| 3 Years: | 21% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 15% |
| 3 Years: | 16% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 2:21 pm
Balance Sheet
Last Updated: December 4, 2025, 2:22 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 13 | 13 | 13 | 13 | 13 | 25 | 25 | 25 | 25 | 25 | 50 |
| Reserves | 82 | 97 | 107 | 128 | 137 | 152 | 150 | 166 | 189 | 216 | 266 | 301 | 277 |
| Borrowings | 0 | 0 | 2 | 0 | 2 | 4 | 45 | 14 | 4 | 1 | 3 | 11 | 0 |
| Other Liabilities | 77 | 67 | 71 | 48 | 57 | 71 | 119 | 128 | 129 | 163 | 152 | 170 | 182 |
| Total Liabilities | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 509 |
| Fixed Assets | 12 | 9 | 18 | 17 | 17 | 21 | 84 | 71 | 61 | 53 | 49 | 58 | 61 |
| CWIP | 0 | 0 | 0 | 0 | 6 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 27 | 43 | 43 | 70 | 66 | 39 | 80 | 31 | 43 | 91 | 97 | 106 | 71 |
| Other Assets | 124 | 116 | 131 | 101 | 120 | 147 | 163 | 230 | 243 | 261 | 300 | 342 | 376 |
| Total Assets | 163 | 168 | 193 | 189 | 209 | 240 | 326 | 333 | 347 | 405 | 446 | 507 | 509 |
Below is a detailed analysis of the balance sheet data for Anuh Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 277.00 Cr.. The value appears to be declining and may need further review. It has decreased from 301.00 Cr. (Mar 2025) to 277.00 Cr., marking a decrease of 24.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 11.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 11.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 182.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 170.00 Cr. (Mar 2025) to 182.00 Cr., marking an increase of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 509.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 507.00 Cr. (Mar 2025) to 509.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2025) to 61.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 71.00 Cr.. The value appears to be declining and may need further review. It has decreased from 106.00 Cr. (Mar 2025) to 71.00 Cr., marking a decrease of 35.00 Cr..
- For Other Assets, as of Sep 2025, the value is 376.00 Cr.. The value appears strong and on an upward trend. It has increased from 342.00 Cr. (Mar 2025) to 376.00 Cr., marking an increase of 34.00 Cr..
- For Total Assets, as of Sep 2025, the value is 509.00 Cr.. The value appears strong and on an upward trend. It has increased from 507.00 Cr. (Mar 2025) to 509.00 Cr., marking an increase of 2.00 Cr..
Notably, the Reserves (277.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 24.00 | 31.00 | 36.00 | 23.00 | 16.00 | 26.00 | -22.00 | 31.00 | 43.00 | 51.00 | 73.00 | 51.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102 | 88 | 84 | 100 | 109 | 85 | 96 | 90 | 102 | 118 | 107 | 119 |
| Inventory Days | 33 | 27 | 35 | 72 | 64 | 64 | 98 | 90 | 77 | 66 | 57 | 54 |
| Days Payable | 102 | 79 | 77 | 102 | 105 | 89 | 166 | 133 | 117 | 139 | 105 | 115 |
| Cash Conversion Cycle | 33 | 36 | 42 | 70 | 68 | 61 | 28 | 48 | 62 | 46 | 58 | 59 |
| Working Capital Days | 42 | 43 | 48 | 79 | 80 | 65 | -10 | 57 | 68 | 61 | 69 | 68 |
| ROCE % | 31% | 33% | 35% | 19% | 14% | 19% | 10% | 16% | 18% | 19% | 26% | 17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| Diluted EPS (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| Cash EPS (Rs.) | 11.19 | 13.70 | 9.15 | 8.48 | 8.68 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 65.06 | 58.11 | 48.14 | 42.66 | 38.04 |
| Dividend / Share (Rs.) | 1.50 | 2.50 | 2.00 | 1.75 | 1.50 |
| Revenue From Operations / Share (Rs.) | 132.01 | 129.11 | 105.26 | 97.11 | 86.20 |
| PBDIT / Share (Rs.) | 14.04 | 17.41 | 11.45 | 10.39 | 11.00 |
| PBIT / Share (Rs.) | 12.30 | 15.70 | 9.52 | 8.00 | 7.99 |
| PBT / Share (Rs.) | 12.17 | 15.63 | 9.47 | 7.81 | 7.69 |
| Net Profit / Share (Rs.) | 9.45 | 11.98 | 7.22 | 6.10 | 5.67 |
| PBDIT Margin (%) | 10.63 | 13.48 | 10.87 | 10.69 | 12.76 |
| PBIT Margin (%) | 9.31 | 12.15 | 9.04 | 8.23 | 9.27 |
| PBT Margin (%) | 9.22 | 12.10 | 8.99 | 8.03 | 8.92 |
| Net Profit Margin (%) | 7.15 | 9.28 | 6.85 | 6.27 | 6.58 |
| Return on Networth / Equity (%) | 14.52 | 20.62 | 14.99 | 14.29 | 14.91 |
| Return on Capital Employeed (%) | 18.78 | 26.84 | 19.57 | 18.53 | 20.73 |
| Return On Assets (%) | 9.34 | 13.47 | 8.93 | 8.80 | 8.54 |
| Total Debt / Equity (X) | 0.03 | 0.01 | 0.00 | 0.01 | 0.07 |
| Asset Turnover Ratio (%) | 1.39 | 1.52 | 1.40 | 1.43 | 1.31 |
| Current Ratio (X) | 2.11 | 2.20 | 1.91 | 1.98 | 1.70 |
| Quick Ratio (X) | 1.69 | 1.71 | 1.46 | 1.37 | 1.12 |
| Inventory Turnover Ratio (X) | 8.83 | 8.74 | 4.94 | 4.36 | 4.53 |
| Dividend Payout Ratio (NP) (%) | 26.45 | 16.68 | 24.23 | 24.59 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 22.33 | 14.60 | 19.11 | 17.67 | 0.00 |
| Earning Retention Ratio (%) | 73.55 | 83.32 | 75.77 | 75.41 | 0.00 |
| Cash Earning Retention Ratio (%) | 77.67 | 85.40 | 80.89 | 82.33 | 0.00 |
| Interest Coverage Ratio (X) | 113.62 | 246.74 | 262.77 | 54.16 | 36.88 |
| Interest Coverage Ratio (Post Tax) (X) | 77.46 | 170.85 | 166.66 | 32.80 | 20.03 |
| Enterprise Value (Cr.) | 736.68 | 1223.09 | 392.34 | 417.88 | 446.02 |
| EV / Net Operating Revenue (X) | 1.11 | 1.89 | 0.74 | 0.85 | 1.03 |
| EV / EBITDA (X) | 10.47 | 14.02 | 6.84 | 8.03 | 8.09 |
| MarketCap / Net Operating Revenue (X) | 1.13 | 1.90 | 0.75 | 0.88 | 1.05 |
| Retention Ratios (%) | 73.54 | 83.31 | 75.76 | 75.40 | 0.00 |
| Price / BV (X) | 2.29 | 4.23 | 1.65 | 2.01 | 2.37 |
| Price / Net Operating Revenue (X) | 1.13 | 1.90 | 0.75 | 0.88 | 1.05 |
| EarningsYield | 0.06 | 0.04 | 0.09 | 0.07 | 0.06 |
After reviewing the key financial ratios for Anuh Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.19. This value is within the healthy range. It has decreased from 13.70 (Mar 24) to 11.19, marking a decrease of 2.51.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
- For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.50 (Mar 24) to 1.50, marking a decrease of 1.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 132.01. It has increased from 129.11 (Mar 24) to 132.01, marking an increase of 2.90.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 14.04. This value is within the healthy range. It has decreased from 17.41 (Mar 24) to 14.04, marking a decrease of 3.37.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.30. This value is within the healthy range. It has decreased from 15.70 (Mar 24) to 12.30, marking a decrease of 3.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 12.17. This value is within the healthy range. It has decreased from 15.63 (Mar 24) to 12.17, marking a decrease of 3.46.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
- For PBDIT Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has decreased from 13.48 (Mar 24) to 10.63, marking a decrease of 2.85.
- For PBIT Margin (%), as of Mar 25, the value is 9.31. This value is below the healthy minimum of 10. It has decreased from 12.15 (Mar 24) to 9.31, marking a decrease of 2.84.
- For PBT Margin (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 10. It has decreased from 12.10 (Mar 24) to 9.22, marking a decrease of 2.88.
- For Net Profit Margin (%), as of Mar 25, the value is 7.15. This value is within the healthy range. It has decreased from 9.28 (Mar 24) to 7.15, marking a decrease of 2.13.
- For Return on Networth / Equity (%), as of Mar 25, the value is 14.52. This value is below the healthy minimum of 15. It has decreased from 20.62 (Mar 24) to 14.52, marking a decrease of 6.10.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has decreased from 26.84 (Mar 24) to 18.78, marking a decrease of 8.06.
- For Return On Assets (%), as of Mar 25, the value is 9.34. This value is within the healthy range. It has decreased from 13.47 (Mar 24) to 9.34, marking a decrease of 4.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.39. It has decreased from 1.52 (Mar 24) to 1.39, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.11, marking a decrease of 0.09.
- For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.69, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.83. This value exceeds the healthy maximum of 8. It has increased from 8.74 (Mar 24) to 8.83, marking an increase of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 26.45. This value is within the healthy range. It has increased from 16.68 (Mar 24) to 26.45, marking an increase of 9.77.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 22.33. This value is within the healthy range. It has increased from 14.60 (Mar 24) to 22.33, marking an increase of 7.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 73.55. This value exceeds the healthy maximum of 70. It has decreased from 83.32 (Mar 24) to 73.55, marking a decrease of 9.77.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 77.67. This value exceeds the healthy maximum of 70. It has decreased from 85.40 (Mar 24) to 77.67, marking a decrease of 7.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 113.62. This value is within the healthy range. It has decreased from 246.74 (Mar 24) to 113.62, marking a decrease of 133.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 77.46. This value is within the healthy range. It has decreased from 170.85 (Mar 24) to 77.46, marking a decrease of 93.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is 736.68. It has decreased from 1,223.09 (Mar 24) to 736.68, marking a decrease of 486.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has decreased from 1.89 (Mar 24) to 1.11, marking a decrease of 0.78.
- For EV / EBITDA (X), as of Mar 25, the value is 10.47. This value is within the healthy range. It has decreased from 14.02 (Mar 24) to 10.47, marking a decrease of 3.55.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
- For Retention Ratios (%), as of Mar 25, the value is 73.54. This value exceeds the healthy maximum of 70. It has decreased from 83.31 (Mar 24) to 73.54, marking a decrease of 9.77.
- For Price / BV (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.23 (Mar 24) to 2.29, marking a decrease of 1.94.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
- Net Profit Margin: 7.15%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.78% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 14.52% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 77.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.6 (Industry average Stock P/E: 43.09)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.03
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.15%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3-A, Shivsagar Estate, Mumbai Maharashtra 400018 | anuh@sk1932.com http://www.anuhpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Todarwal | Chairman & Non-Exe.Director |
| Mr. Bipin N Shah | Vice Chairman & Non Exe.Dire |
| Mr. Ritesh B Shah | Joint Managing Director |
| Mr. Vivek B Shah | Joint Managing Director |
| Mr. Bharat Shah | Non Executive Director |
| Mr. Samir Shah | Non Executive Director |
| Mr. Gaurav S Shah | Non Executive Director |
| Mr. Ketan Shah | Non Executive Director |
| Dr.(Ms.) Mita Dixit | Independent Director |
| Mr. Siddharth J Shah | Independent Director |
| Mr. Pradeep H Thakur | Independent Director |
| Mr. Harmanbhai Patel | Independent Director |
FAQ
What is the intrinsic value of Anuh Pharma Ltd?
Anuh Pharma Ltd's intrinsic value (as of 11 December 2025) is 73.35 which is 7.85% lower the current market price of 79.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 797 Cr. market cap, FY2025-2026 high/low of 123/74.0, reserves of ₹277 Cr, and liabilities of 509 Cr.
What is the Market Cap of Anuh Pharma Ltd?
The Market Cap of Anuh Pharma Ltd is 797 Cr..
What is the current Stock Price of Anuh Pharma Ltd as on 11 December 2025?
The current stock price of Anuh Pharma Ltd as on 11 December 2025 is 79.6.
What is the High / Low of Anuh Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Anuh Pharma Ltd stocks is 123/74.0.
What is the Stock P/E of Anuh Pharma Ltd?
The Stock P/E of Anuh Pharma Ltd is 20.6.
What is the Book Value of Anuh Pharma Ltd?
The Book Value of Anuh Pharma Ltd is 32.6.
What is the Dividend Yield of Anuh Pharma Ltd?
The Dividend Yield of Anuh Pharma Ltd is 1.89 %.
What is the ROCE of Anuh Pharma Ltd?
The ROCE of Anuh Pharma Ltd is 17.2 %.
What is the ROE of Anuh Pharma Ltd?
The ROE of Anuh Pharma Ltd is 13.4 %.
What is the Face Value of Anuh Pharma Ltd?
The Face Value of Anuh Pharma Ltd is 5.00.